Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | ABL2 | P42684 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917994 | 0.83 | MAPK1 (0.58) | EGFRFBP1MKNK1ABL1ABL2 | |
| SCHEMBL4913660 | 0.83 | TTBK1 (0.63) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL4922638 | 0.83 | HTT (0.65) | EGFRABL1ABL2ERBB2 | |
| SCHEMBL16146468 | 0.82 | BRAF (0.67) | EGFRAURKAAURKBINCENPBRAF | |
| SCHEMBL4921635 | 0.82 | MKNK1 (0.54) | EGFRAURKAAURKBINCENPFBP1 | |
| Hydrochloric Acid SCHEMBL7537154 | 0.82 | TTBK1 (0.61) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL891009 | 0.82 | TTBK1 (0.57) | EGFRAURKBABL1ABL2ABCG2 | |
| SCHEMBL20119339 | 0.80 | EGFR (0.58) | EGFRABCG2BRAF | |
| SCHEMBL16146388 | 0.80 | EGFR (0.52) | EGFRAURKAAURKBINCENPFBP1 | |
| SCHEMBL7542136 | 0.80 | AURKA (0.55) | EGFRAURKAAURKBFBP1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | claimed |
| EP-1419157-A2 | HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2004-05-19 | — | — | EP | claimed |
| WO-2003040144-A2 | HETEROCYCLIC COMPOUND BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-05-15 | — | — | WO | claimed |
| CN-1139383-A | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | claimed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-8552013-B2 | Heterocyclic compounds based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2013-10-08 | — | — | US | disclosed |
| US-20080014227-A1 | HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2008-01-17 | — | — | US | disclosed |
| US-7279482-B2 | Heterocyclic compound based on N6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | Ústav experimentálni botaniky Akademie ved Ceské republiky (CZ) | 2007-10-09 | — | — | US | disclosed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | disclosed |
| EP-1419157-A2 | HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2004-05-19 | — | — | EP | disclosed |
| US-6713484-B2 | FUSED RING PYRIMIDINE DERIVATIVES; LOW CYTOTOXICITY | WARNER-LAMBERT COMPANY | 2004-03-30 | — | — | US | disclosed |
| WO-2003040144-A2 | HETEROCYCLIC COMPOUND BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-05-15 | — | — | WO | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | EGFR 4677/4885AURKA 4599/4885AURKB 3838/4885 |
| US-20080014227-A1 | HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | TYMP, CCNB1, CCNA2 | EGFR 533/4885AURKA 187/4885AURKB 246/4885 |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ATIC, UMPS, CCNB1 | EGFR 1550/4885AURKA 417/4885AURKB 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.